• About Us
  • Strategy
  • Our Team
  • Portfolio
  • News
  • Contact
  • Building Market-Leading Healthtech Companies

    About Us
    Header Pattern

    Sector Focus

    Medical Devices

    Tools & Diagnostics

    Digital Health

    Tech-Enabled Services

    Our Strategy


    Leaders in Healthcare Technology Investing

    See All
    Ai Cure StandardLogo retinaCogentix Logo RGB 300x96EndoKeystone 1Med Minder removebg previewNeuro Pace Logo Vert rgb largeStrataVeranexMinerva logo reg 2xSknv


    "We take a private equity approach to a sector that’s traditionally been dominated by venture and early-stage growth firms. We'll work very closely with management to improve the operations of the business, update the product portfolio and revamp the commercial organization. We provide the support and resources our portfolio companies need to succeed.”

    Meet Our Team
    active portfolio companies
    employees worldwide
    AP-II Investments to Date
    successful exits


    Jul 17, 2024

    Merit Medical Announces Asset Purchase Agreement with EndoGastric Solutions, Inc.

    Asset acquisition expands Merit’s endoscopy portfolio with a minimally invasive solution for patients suffering from chronic gastroesophageal reflux disease (GERD)

    Read More

    May 22, 2024

    Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.

    Better Therapeutics assets include the first FDA-authorized prescription digital therapeutic for type 2 diabetes, AspyreRx, as well as development candidates BT-002, BT-003 and BT-004 for hypertension, hyperlipidemia, and MASH. Initial efforts will focus on further development of AspyreRx to adapt it for the treatment of obesity and to benefit from Click’s AI-enabled platform as part of Click’s obesity digital therapeutic in development, CT-181; Click does not plan to self-commercialize AspyreRx as-is at this time. CT-181 will be optimized for combination use with anti-obesity and diabetes medications such as GLP-1s, including current injectables and future oral formulations, with the goal of improving treatment persistence, outcomes, and value.

    Apr 01, 2024

    Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms

    In a landmark clinical study, this innovative adjunctive treatment delivered via smartphone app reduced depression symptoms in participants on antidepressant medication with no treatment-related adverse events

    Jan 08, 2024

    NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates

    Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and between $64.9 million and $65.4 million for full year 2023, beginning 2024 with cash balance of $66.5 million. Announced completion of patient implant milestone in the NAUTILUS trial. Completed initial milestones in first strategic data collaboration, using proprietary biomarker monitoring and data analysis capabilities to support a clinical-stage biotechnology company’s clinical trial. Pilot Launch of Project CARE program to advance RNS System access to community setting expected in 1H 2024.

    Contact Us

    Partner with Us

    Get in touch